Chuzhou Qingyun Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing enterprise specializing in the research and development, production and trade of active pharmaceutical ingredients and pharmaceutical intermediates. The company was established on July 28, 2016, and is located on the north side of Yanhua Avenue in the Yanhua Industrial Park, Dingyuan County, Chuzhou City, with a registered capital of 18 million yuan.

Chuzhou Qingyun covers an area of 91 mu. The first phase has built one statin dedicated workshop, one 5,000-square-meter multi-functional workshop, one quality inspection office building, seven warehouses and power auxiliary facilities, etc. The company has over 180 reaction vessels with capacities ranging from 200 to 10,000 liters, covering reactions such as hydrogenation, oxidation, alkylation, and ultra-low temperature. The total reaction volume is 166,200 liters, and the wastewater treatment capacity reaches 500 cubic meters per day. Additionally, it is equipped with more than 50 sets of scientific research and testing instruments and equipment.

The company has a sufficient number of professional and technical personnel and a high intensity of R&D investment, which provides an inexhaustible driving force for the innovative development of the enterprise. So far, more than 50 invention patents have been applied for, among which 30 have been authorized (including 3 US invention patents).

The company has established a product pattern that combines cardiovascular and central nervous system products. The product quality is in accordance with USP, EP, JP and CP standards, and the products are exported to more than ten countries including Japan, South Korea and India. At present, the company is actively preparing to become the "world's number one brand of specialty generic drugs and intermediates", and has already become a first-tier supplier for the top three generic drug pharmaceutical companies worldwide (TEVA from Israel, SANDOZ from Germany, and DSM from the Netherlands). Especially in the two product segments of rosuvastatin calcium and renozidine, the company has stable sales channels and high-end customer resources. Currently, the company's new projects mainly include kalidazine, pazoparib, and ganirex acetate. It strives to become the world's number one in these two varieties by 2025.